Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of Prematurity

被引:125
作者
Kong, Lingkun [1 ]
Bhatt, Amit R. [1 ]
Demny, Ann B. [2 ]
Coats, David K. [1 ]
Li, Alexa [3 ]
Rahman, Effie Z. [3 ]
Smith, O'Brian E. [4 ]
Steinkuller, Paul G. [1 ]
机构
[1] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
[3] Baylor Coll Med, Sch Med, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Pediat & Biostat, Houston, TX 77030 USA
关键词
retinopathy of prematurity; laser; intraocular injection; bevacizumab; VEGF; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL INJECTION; MACULAR DEGENERATION; PLASMA-LEVELS; ANTIBODIES; RANIBIZUMAB; SURVIVAL; EFFICACY;
D O I
10.1167/iovs.14-15842
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To measure serum levels of bevacizumab and to compare serum levels of free vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in infants who were treated with either intravitreal injection of bevacizumab (IVB) or laser for type 1 retinopathy of prematurity (ROP). METHODS. Twenty-four infants with type 1 ROP were randomized into three treatment groups: IVB at 0.625 mg per eye per dose, IVB at 0.25 mg per eye per dose, and laser. Blood samples were collected prior to treatment and on posttreatment days 2, 14, 42, and 60. Weekly body weights were documented from birth until 60 days post treatment. Serum levels of bevacizumab, free VEGF, and IGF-1 were measured with enzyme-linked immunosorbent assay (ELISA). RESULTS. Serum bevacizumab was detected 2 days after the injection, peaked at 14 days, and persisted for up to 60 days with half-life of 21 days. Area under the curve (AUC) analysis showed that systemic exposure to bevacizumab was variable among the subjects and was dose dependent. Serum free VEGF levels decreased in all three subgroups 2 days post treatment, with more significant reductions found in both IVB-treated groups, P = 0.0001. Serum IGF-1 levels were lower in both IVB-treated groups. CONCLUSIONS. Clearance of bevacizumab from the bloodstream in premature infants takes at least 2 months. Although serum free VEGF levels decreased following either laser or bevacizumab treatment, the reductions were more significant in the IVB-treated groups. Potential long-term effects of systemic exposure to bevacizumab in infants need to be studied further.
引用
收藏
页码:956 / 961
页数:6
相关论文
共 32 条
[1]   HYPOXIC REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN RETINAL CELLS [J].
AIELLO, LP ;
NORTHRUP, JM ;
KEYT, BA ;
TAKAGI, H ;
IWAMOTO, MA .
ARCHIVES OF OPHTHALMOLOGY, 1995, 113 (12) :1538-1544
[2]   Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD [J].
Avery, Robert L. ;
Castellarin, Alessandro A. ;
Steinle, Nathan C. ;
Dhoot, Dilsher S. ;
Pieramici, Dante Joseph ;
See, Robert ;
Couvillion, Stephen ;
Nasir, Ma'an A. ;
Rabena, Melvin D. ;
Le, Kha ;
Maia, Mauricio ;
Visich, Jennifer E. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (12) :1636-1641
[3]   VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vessels [J].
Cariboni, Anna ;
Davidson, Kathryn ;
Dozio, Elena ;
Memi, Fani ;
Schwarz, Quenten ;
Stossi, Fabio ;
Parnavelas, John G. ;
Ruhrberg, Christiana .
DEVELOPMENT, 2011, 138 (17) :3723-3733
[4]   Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab [J].
Carneiro, Angela M. ;
Costa, Raquel ;
Falcao, Manuel S. ;
Barthelmes, Daniel ;
Mendonca, Luis S. ;
Fonseca, Sofia L. ;
Goncalves, Rita ;
Goncalves, Conceicao ;
Falcao-Reis, Fernando M. ;
Soares, Raquel .
ACTA OPHTHALMOLOGICA, 2012, 90 (01) :E25-E30
[5]   GROWTH-PATTERNS OF LOW-BIRTH-WEIGHT PRETERM INFANTS - A LONGITUDINAL ANALYSIS OF A LARGE, VARIED SAMPLE [J].
CASEY, PH ;
KRAEMER, HC ;
BERNBAUM, J ;
TYSON, JE ;
SELLS, JC ;
YOGMAN, MW ;
BAUER, CR .
JOURNAL OF PEDIATRICS, 1990, 117 (02) :298-307
[6]   Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity [J].
Chung, Eun Jee ;
Kim, Ji Hyun ;
Ahn, Hyun Seok ;
Koh, Hyoung Jun .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (11) :1727-1730
[7]   Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy [J].
Davidovic, Sofija P. ;
Nikolic, Stanislava V. ;
Curic, Nikola J. ;
Latinovic, Slobodanka L. J. ;
Draskovic, Dragan O. ;
Cabarkapa, Velibor S. ;
Stosic, Zoran Z. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2012, 22 (05) :792-798
[8]   Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications [J].
Edelhauser, Henry F. ;
Rowe-Rendleman, Cheryl L. ;
Robinson, Michael R. ;
Dawson, Daniel G. ;
Chader, Gerald J. ;
Grossniklaus, Hans E. ;
Rittenhouse, Kay D. ;
Wilson, Clive G. ;
Weber, David A. ;
Kuppermann, Baruch D. ;
Csaky, Karl G. ;
Olsen, Timothy W. ;
Kompella, Uday B. ;
Holers, V. Michael ;
Hageman, Gregory S. ;
Gilger, Brian C. ;
Campochiaro, Peter A. ;
Whitcup, Scott M. ;
Wong, Wai T. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (11) :5403-5420
[9]   VEGF Signaling through Neuropilin 1 Guides Commissural Axon Crossing at the Optic Chiasm [J].
Erskine, Lynda ;
Reijntjes, Susan ;
Pratt, Thomas ;
Denti, Laura ;
Schwarz, Quenten ;
Vieira, Joaquim M. ;
Alakakone, Bennett ;
Shewan, Derryck ;
Ruhrberg, Christiana .
NEURON, 2011, 70 (05) :951-965
[10]   Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells [J].
Fukuda, R ;
Hirota, K ;
Fan, F ;
Do Jung, Y ;
Ellis, LM ;
Semenza, GL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (41) :38205-38211